Vimarsana
Biggest News Aggregation in the World

Page 6 - Stent System News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stent System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stent System Today - Breaking & Trending Today

Top Midday Decliners - Vimarsana News

Top Midday Decliners

-- Silk Road Medical shares sank 50% amid heavy trading after the company, late Tuesday, lowered its projections for full-year 2023 sales. Piper Sandler cut its price target for the company's...

Silk Road Medical, Inc (NASDAQ:SILK) Receives $37.60 Average Target Price from Brokerages - Vimarsana News

Silk Road Medical, Inc (NASDAQ:SILK) Receives $37.60 Average Target Price from Brokerages

Silk Road Medical, Inc (NASDAQ:SILK – Get Free Report) has earned a consensus rating of “Hold” from the nine research firms that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to […]

Cardiovascular Crisis Meets Cutting-Edge Solutions: Insights from the Peripheral Vascular Stents Market Report - Vimarsana News

Cardiovascular Crisis Meets Cutting-Edge Solutions: Insights from the Peripheral Vascular Stents Market Report

/PRNewswire/ -- The "Peripheral Vascular Stents Market Size, Share & Trends Analysis Report, 2023 - 2030" has been added to ResearchAndMarkets.com's offering....

Silk Road Medical (NASDAQ:SILK) versus Insulet (NASDAQ:PODD) Financial Contrast - Vimarsana News

Silk Road Medical (NASDAQ:SILK) versus Insulet (NASDAQ:PODD) Financial Contrast

Silk Road Medical (NASDAQ:SILK – Get Free Report) and Insulet (NASDAQ:PODD – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a summary of current […]

First-on-Podium Data from 20 Vascular and Venous Clinical Trials to Be Presented at The VEINS and VIVA 2023 - Vimarsana News

First-on-Podium Data from 20 Vascular and Venous Clinical Trials to Be Presented at The VEINS and VIVA 2023

/PRNewswire/ -- Leading physicians and researchers will present results from 20 clinical trials from Monday, October 30, to Wednesday, November 1, at the...